Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are conducting a phase 3, randomized, double-blind study to evaluate the effectiveness of Ivonescimab combined with mFOLFOX6 versus Bevacizumab combined with mFOLFOX6 for the first-line treatment of metastatic colorectal cancer. The trial includes patients who have not previously received systemic therapy for metastatic disease and aims to compare these treatments in a controlled setting. Participants will be randomly assigned to one of two treatment groups Ivonescimab plus mFOLFOX6 or Bevacizumab plus mFOLFOX6. Both treatments are given by intravenous infusion every two weeks for up to eight cycles. After these initial treatment cycles, maintenance therapy with Ivonescimab or Bevacizumab combined with Leucovorin and 5-Fluorouracil will be administered every two weeks for up to two years. Throughout the study, participants will undergo regular assessments to monitor disease progression using standardized imaging criteria. Researchers will evaluate progression-free survival as the primary outcome over approximately 2.5 years, alongside secondary outcomes including overall survival, tumor response rate, duration of response, and adverse events over up to 4 years. Study-related care and follow-up will be conducted during this period to assess treatment effects and safety.
Actively Recruiting
Researchers are evaluating the drug ruxolitinib in people with low-risk but symptomatic essential thrombocythemia ET and polycythemia vera PV. This phase II clinical trial aims to see if ruxolitinib can reduce the symptoms caused by these blood conditions. The study is supported by a biopharmaceutical company and involves patients diagnosed according to specific medical criteria and who have significant symptoms. Participants will receive ruxolitinib pills taken twice daily in 28-day treatment cycles. The trial includes two stages in the first stage, participants receive six cycles of ruxolitinib, and if at least three participants respond positively, the second stage will proceed with similar treatment. Those benefiting from the drug may continue treatment as long as side effects or disease progression do not occur. During the study, participants will undergo screening, evaluations, and follow-up visits. Researchers will measure symptom changes using the Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score over 12 weeks as the primary outcome. Other assessments include blood counts, spleen volume, and monitoring of treatment-related side effects. The total study duration and ongoing monitoring may extend up to 60 months.
Actively Recruiting
Researchers are evaluating sacituzumab govitecan for people with localized triple negative breast cancer TNBC in this Phase II clinical trial. The study aims to assess the safety and effectiveness of this investigational drug, alone or combined with pembrolizumab, in treating this specific type of breast cancer. This trial is part of an umbrella study exploring different treatment options for breast cancer patients, including future arms for hormone receptor positive and inflammatory breast cancers. Participants will receive sacituzumab govitecan through intravenous infusions on two days every 21-day cycle, for up to four cycles approximately 12 weeks. After completing the sacituzumab govitecan monotherapy cohort, a combination therapy cohort with pembrolizumab will open. Some participants may also receive standard chemotherapy afterward, based on their doctors decision. The study includes screening, treatment, evaluations, and follow-up visits. During the study, participants will undergo various assessments including biopsies, laboratory tests, and evaluations to monitor response and safety. Researchers will measure outcomes such as the pathological complete response rate at 12 weeks, disease-free survival, overall survival, quality of life, and treatment-related side effects. The total participant involvement may last up to 36 months for long-term monitoring of outcomes and safety.
Actively Recruiting
Researchers are evaluating the effects of oral rilzabrutinib in adults with immune thrombocytopenia ITP who have not responded to first-line treatment. This multinational, open-label, single-arm study focuses on early multi-immune modulation to manage ITP symptoms and improve platelet response. The trial is sponsored by Sanofi and is designed as a Phase 3 treatment study. Participants will receive rilzabrutinib tablets orally at a dose of 400 mg twice daily. The study is divided into several periods a screening phase lasting up to 8 weeks, a primary analysis phase of up to 28 weeks where the main treatment effects are assessed, followed by a long-term extension phase of 28 weeks for selected participants. Additionally, there is a 24-week follow-up period for eligible participants after treatment. During the study, participants will be monitored regularly to evaluate platelet response and bleeding symptoms using the immune thrombocytopenia bleeding scale, as well as their ability to reduce corticosteroid doses. Safety assessments will track adverse events and clinically significant abnormalities throughout the study, including the extension and follow-up phases. The total duration of participation may extend up to approximately 80 weeks, depending on individual eligibility for the long-term and follow-up periods.